AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 1760713
Drug: MCT/LCT solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT/LCT solution
Trial: 1760713
Drug: LCT solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT solution
Trial: 1760713
Drug: LCT-containing solution
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LCT-containing solution
Trial: 1760713
Drug: MCT-containing solutions
RxNorm normalized name: MCT
DrugBank: Medium-chain triglycerides (DB13959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MCT-containing solutions
Trial: 6291361
Drug: Captopril (CPT)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CPT) 6.25 mg
Trial: 6291361
Drug: Captopril (CPT)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CPT) 12.5 mg
Trial: 6291361
Drug: Captopril (CPT)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CPT) 12.5 to 50 mg every 8 hours long-term
Trial: 6291361
Drug: Captopril (CPT)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (CPT) 25 mg
Trial: 22898037
Drug: Cetuximab plus
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab plus bevacizumab (15 mg/kg on day 1 given intravenously every 21 days until disease progression)
Trial: 21471258
Drug: Bupivacaine group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine group (20 mL bupivacaine 0.25% and 0.5 mL adrenaline 1/200,000 each side)
Trial: 21471258
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20.5 mL normal saline each side)
Trial: 11158752
Drug: Gemifloxacin 160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 160 mg once daily for 7 days
Trial: 11158752
Drug: Gemifloxacin 480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 480 mg once daily for 7 days
Trial: 11158752
Drug: Gemifloxacin 640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin 640 mg once daily for 7 days
Trial: 11158752
Drug: Gemifloxacin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemifloxacin (all doses)
Trial: 1335650
Drug: Hepatitis A
RxNorm normalized name: HEPATITIS A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatitis A vaccine (SmithKline Beecham Biologicals)
Trial: 27109264
Drug: Taurine (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Taurine (6 g)
Trial: 27109264
Drug: Placebo (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (6 g dextrose)
Trial: 15943592
Drug: Intravenous hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous hydrocortisone (30 microg/m(2) body surface area/24 h)
Trial: 12861239
Drug: Abbreviated Progressive
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Abbreviated Progressive Muscle Relaxation Therapy (APRT)
Trial: 10774661
Drug: SB MMR
RxNorm normalized name: MMR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SB MMR vaccine
Trial: 10774661
Drug: Merck MMR
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain Injection [Varivax]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Merck MMR vaccine
Trial: 8683240
Drug: Tamoxifen (160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamoxifen (160 mg orally daily for 7 days before chemotherapy and 40 mg orally daily throughout the treatment cycle)
Trial: 8683240
Drug: Placebo (given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (given with the same chemotherapy regimen)
Trial: 1929686
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 0.3 mg
Trial: 1929686
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 0.625 mg
Trial: 1929686
Drug: Estrone sulfate
RxNorm normalized name: Estrone sulfate
DrugBank: Estrone sulfate (DB04574)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estrone sulfate 1.25 mg
Trial: 3881155
Drug: Incision, curettage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incision, curettage and primary suture without parenteral antibiotics (64 cases)
Trial: 3881155
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with incision, drainage and dressings (73 cases)
Trial: 29981863
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (chronic DOAC administration)
Trial: 22145978
Drug: Conventional SLA
RxNorm normalized name: slash pine pollen extract
DrugBank: Pinus elliottii pollen (DB10747)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional SLA implants
Trial: 22145978
Drug: Chemically modified
RxNorm normalized name: Chemically modified recombinant sulfamidase
DrugBank: SOBI-003 (DB15451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemically modified SLA (modSLA) implants
Trial: 12707465
Drug: Continuous therapy
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous therapy (3-5 mg/kg/day initially, then 0.5-3 mg/kg/day after remission)
Trial: 12707465
Drug: Intermittent therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent therapy (3-5 mg/kg/day initially, then tapered off after remission)
Trial: 10784478
Drug: Divalproex treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex treatment for 6 weeks
Trial: 10784478
Drug: Divalproex treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex treatment for 6 weeks (in subjects who completed both phases)
Trial: 8982753
Drug: Oestradiol patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol patch (100 micrograms/day for 6 weeks)
Trial: 8982753
Drug: Oestradiol patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oestradiol patch
Trial: 6150945
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg propranolol
Trial: 30203757
Drug: Nasal continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal continuous positive airway pressure plus high-dose ambroxol
Trial: 26263283
Drug: 0.1 mg/hour
RxNorm normalized name: nitroglycerin 0.1 mg/hour TRANSDERM PATCH, TRANSDERMAL 24 HOURS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mg/hour nitroglycerin patch applied daily, escalating to 0.2, 0.4, or 0.6 mg/hour as tolerated
Trial: 26263283
Drug: Discontinuation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinuation of nitroglycerin
Trial: 7600653
Drug: Carvedilol (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (up to 25 mg BID)
Trial: 2194642
Drug: Metoclopramide (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) without Dexamethasone
Trial: 2194642
Drug: Metoclopramide (2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (2.0 mg/kg) and Lorazepam (1.5 mg/m2) with Dexamethasone (0.5 mg/kg)
Trial: 221114
Drug: Cyclic alternating
RxNorm normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclic alternating combination chemotherapy with high‐dose cyclophosphamide, methotrexate, and CCNU (CMC) followed by vincristine, adriamycin, and procarbazine (VAP) for 6 weeks each.
Trial: 221114
Drug: Addition of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Addition of VAP after CMC treatment.
Trial: 30278430
Drug: Resveratrol 100
RxNorm normalized name: resveratrol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 100 mg/d
Trial: 30278430
Drug: Placebo (sucrose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sucrose 0.5 g/d)
Trial: 23328268
Drug: Clopidogrel napadisilate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel napadisilate plus aspirin
Trial: 23328268
Drug: Clopidogrel bisulfate
RxNorm normalized name: Clopidogrel Bisulfate
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Clopidogrel bisulfate plus aspirin
Trial: 16580587
Drug: Pistachio diet
RxNorm normalized name: Pistachio
DrugBank: Pistachio (DB10559)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pistachio diet (substituting pistachio nuts for 20% of daily caloric intake for 3 weeks)
Trial: 10902094
Drug: Serotonin-reuptake inhibitors
RxNorm normalized name: serotonin
DrugBank: Serotonin (DB08839)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serotonin-reuptake inhibitors
Trial: 10902094
Drug: Buspirone, mood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone, mood stabilizers, beta-blockers
Trial: 9229615
Drug: Cordipin chronotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cordipin chronotherapy (10 mg once a day based on chronosensitivity)
Trial: 9229615
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment with cordipin (10 mg 3 times a day)
Trial: 2934557
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg adjuvant medroxyprogesterone 3 times a week for 1 year
Trial: 28557043
Drug: Nurse-led psychological
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurse-led psychological intervention programme (seven weekly counselling sessions)
Trial: 25550013
Drug: Autologous blood
RxNorm normalized name: Banked autologous blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Autologous blood injection (2 ml of autologous venous blood mixed with 1 ml of 2% prilocaine hydrochloride)
Trial: 25550013
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection (1 ml of 40 mg methylprednisolone acetate mixed with 1 ml of 2% prilocaine hydrochloride)
Trial: 11732218
Drug: Topical Beta-blockers
RxNorm normalized name: Beta-HC Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Beta-blockers and steroids
Trial: 23614393
Drug: Lacosamide 200
RxNorm normalized name: lacosamide 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lacosamide 200 mg twice daily on days 1-9 with a single 25 mg dose of warfarin coadministered on day 3
Trial: 23614393
Drug: Warfarin alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warfarin alone (25 mg)
Trial: 20429947
Drug: Online treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online treatment program for GAD, E‐couch
Trial: 20429947
Drug: Sertraline (25-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (25-100 mg/day)
Trial: 8601640
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion (27 microgram over 100 min) during normoglycemic hyperinsulinemic conditions
Trial: 8601640
Drug: Bradykinin infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bradykinin infusion (27 microgram over 100 min) in the basal state
Trial: 3879175
Drug: Suprofen syrup
RxNorm normalized name: Suprofen
DrugBank: Suprofen (DB00870)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Suprofen syrup (5-7.5 mg/kg b.w., orally)
Trial: 3879175
Drug: L PDP
RxNorm normalized name: L-377202
DrugBank: L-377202 (DB19022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L PDP ear drops (1 drop, locally)
Trial: 27749377
Drug: Case management
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Case management intervention (details on dosage and duration not specified)
Trial: 27382934
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg intravenous hyoscine-N-butylbromide
Trial: 27382934
Drug: Intravenous saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous saline solution (placebo)
Trial: 17593071
Drug: 0.1 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 mol/L hydrochloric acid infusion (150 mL at 15 mL/min for 10 min)
Trial: 17593071
Drug: Pure water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pure water infusion (150 mL)
Trial: 11549532
Drug: Inhaled formoterol
RxNorm normalized name: formoterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled formoterol dry powder 12 or 24 microg twice daily
Trial: 11549532
Drug: Ipratropium bromide
RxNorm normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide 40 microg four times daily
Trial: 3415801
Drug: Ketanserin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (40 mg every 12 hours)
Trial: 29297958
Drug: Topically applied
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topically applied clobetasol propionate 0.05% (mixed with 4% hydroxyethyl cellulose gel)
Trial: 29297958
Drug: 4% hydroxyethyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% hydroxyethyl cellulose gel alone (placebo)
Trial: 26924818
Drug: Axomadol (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Axomadol (doses ranging from 66 mg to 225 mg)
Trial: 26285662
Drug: Acute simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acute simvastatin treatment
Trial: 23659755
Drug: Sotrastaurin 300
RxNorm normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrastaurin 300 mg
Trial: 23659755
Drug: Sotrastaurin 200
RxNorm normalized name: Sotrastaurin
DrugBank: Sotrastaurin (DB12369)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sotrastaurin 200 mg
Trial: 7559885
Drug: Intravenous GHRP-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous GHRP-2
Trial: 7559885
Drug: Intranasal GHRP-2
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal GHRP-2 (5-20 micrograms/kg per dose)
Trial: 7559885
Drug: GHRH +
RxNorm normalized name: GHRH(1-44)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GHRH + GHRP-2 (administered simultaneously)
Trial: 7559885
Drug: Conventional agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional agents (arginine, L-dopa/exercise, insulin)
Trial: 7197960
Drug: Quinidine (492
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (492 mg quinidine-base as quinidine-bisulfate)
Trial: 7448345
Drug: Quinidine formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine formulation 1
Trial: 7448345
Drug: Quinidine formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine formulation 2
Trial: 28334675
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (TAU) (n=20)
Trial: 25987642
Drug: S-ketamine (0.006
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-ketamine (0.006 mg/Kg)
Trial: 22948968
Drug: Doxorubicin 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin 30 mg/m²
Trial: 22948968
Drug: Daunorubicin 30
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 30 mg/m²
Trial: 22948968
Drug: Daunorubicin 40
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Daunorubicin 40 mg/m²
Trial: 7836510
Drug: Oestrogen-progestin add-back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestrogen-progestin add-back therapy (0.75 mg oestropipate daily + 0.7 mg norethindrone on days 1-14 each month)
Trial: 7836510
Drug: Progestin add-back
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progestin add-back therapy (10 mg norethindrone daily)
Trial: 7836510
Drug: Leuprolide acetate
RxNorm normalized name: Leuprolide Acetate
DrugBank: Leuprolide (DB00007)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leuprolide acetate depot (3.75 mg every 4 weeks for 2 years)
Trial: 2972550
Drug: Co-dergocrine (DA2-agonist)
RxNorm normalized name: co-dergocrine mesylate
DrugBank: Ergoloid mesylate (DB01049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-dergocrine (DA2-agonist)
Trial: 31669193
Drug: AS37-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS37-adjuvanted vaccine (TLR7a dose 12.5, 25, 50, 100 μg)
Trial: 31669193
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (licensed MenC conjugate alum-adjuvanted vaccine)
Trial: 31669193
Drug: AS37-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS37-adjuvanted vaccine (TLR7a 100 μg)
Trial: 25833032
Drug: AmED 500
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmED 500 ml energy drink (ED)
Trial: 25833032
Drug: AmED 750
RxNorm normalized name: Encora AM Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AmED 750 ml energy drink (ED)
Trial: 23499420
Drug: Slow-tempo music
RxNorm normalized name: Slow-Fe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-tempo music listening (two 1-hour daily periods)
Trial: 19680456
Drug: Valacyclovir 1
RxNorm normalized name: valacyclovir 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valacyclovir 1 g daily
Trial: 14961155
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of antithrombin III (6 vials: 3000 units) once daily for 5 days or until delivery
Trial: 14961155
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of antithrombin III (sufficient to maintain at least 80% activity)
Trial: 14961155
Drug: High doses
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High doses of antithrombin III
Trial: 14961155
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (high doses and standard doses)
Trial: 12501151
Drug: Sucralfate (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sucralfate (60 mg/kg/d in 4 doses via nasogastric tube)
Trial: 12501151
Drug: Ranitidine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (2 mg/kg/d intravenously in 4 doses)
Trial: 12501151
Drug: Omeprazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole (1 mg/kg/d intravenously in 2 doses)
Trial: 7619035
Drug: Inhalation rewarming
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhalation rewarming with the Heat Treat
Trial: 2096602
Drug: AT877 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT877 20 mg
Trial: 2096602
Drug: AT877 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT877 40 mg
Trial: 2096602
Drug: AT877 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT877 60 mg
Trial: 2096602
Drug: AT877 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT877 90 mg
Trial: 2096602
Drug: AT877 120-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AT877 120-180 mg
Trial: 24108314
Drug: Cinacalcet (30-180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30-180 mg daily)
Trial: 21723949
Drug: Low-dose S-ketamine
RxNorm normalized name: (S)-(-)-ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-dose S-ketamine (0.1mg/kg bolus for 5min, continuous infusion of 0.015625mg/kg/min reduced by 10% every ten minutes)
Trial: 16442905
Drug: No coronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No coronary artery disease, second or greater episode of AF, left ventricular ejection fraction < 0.50, and mitral valve thickening (in patients not taking antiarrhythmic drug therapy)
Trial: 16442905
Drug: Left atrial
RxNorm normalized name: Echinacea, aerial parts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Left atrial diameter > 4.5 cm and mitral valve thickening (in patients taking antiarrhythmic medication)
Trial: 8323383
Drug: Hydroxychloroquine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (400 mg daily for 12 months)
Trial: 3547300
Drug: Tocopherol (adjusted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocopherol (adjusted to plasma levels of 3 to 3.5 mg/dL)
Trial: 23067920
Drug: Once daily
RxNorm normalized name: GEL, ONCE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily aspirin (150 mg in the morning)
Trial: 23067920
Drug: Twice daily
RxNorm normalized name: CAPSULE, TWICE DAILY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice daily aspirin (75 mg in the morning and 75 mg in the evening)
Trial: 20052721
Drug: 3-hour infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hour infusion of paclitaxel at a dose of 250 mg/m² iv every 21 days